See the Northwestern University Press release on the first in human phase 0 clinical trials of Spherical Nucleic Acids.
Dr. Stegh received an R01 grant entitled “Systemic RNA interference to reactivate p53 tumor suppression” (NCI 1R01CA208783).
Dr. Stegh’s laboratory is an integral part of the Northwestern University’s Center for Cancer Nanotechnology Excellence and the Northwestern Brain Tumor Specialized Programs of Research Excellence (SPORE).
About Our Lab
Our research program is aimed at understanding the genetic program that underlies the pathogenesis of Glioblastoma multiforme (GBM), the most prevalent and malignant form of brain cancer. Applying a combination of cell/molecular biology, oncogenomic and mouse engineering approaches, we are dedicated to systematically characterize novel gliomagenic oncogenes and tumor suppressors. We will functionally delineate and validate these pathways towards pharmaceutical opportunities using sophisticated cell culture and animal models.
Please read our latest publications:
Calvert et al., 2017. Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation. Cell Rep. 2017;19(9):1858-1873.
Sita et al., 2017. Dual bioluminescence and near-infrared fluorescence monitoring to evaluate spherical nucleic acid nanoconjugate activity in vivo. Proc Natl Acad Sci U S A. 114(16):4129-4134.